Peter Shalit, MD
Internal Medicine · Seattle, WANPI 1831181700
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $678,253 of the $1,010,691 with a category attached, or 67.1%. 34 manufacturers reported payments, led by Viiv Healthcare Company at 50.6% of the total. Among internal medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,400 payments — averaging $721.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$511K
- Gilead$259K
- EMD Serono, Inc.$131K
- Janssen Scientific Affairs, LLC$42K
- Merck$33K
- Janssen Products, LP$23K
- plus $11K from 28 others
Across 276 payments — averaging $6247.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$918K
- Viiv Healthcare Company$454K
- Merck$218K
- AbbVie$78K
- Janssen Research & Development, LLC$48K
- Seqirus USA Inc$8K
What the payments were for
- Consulting fees$147,75615%
- Speaking & faculty fees$678,25367%
- Travel & lodging$150,43915%
- Food & beverage$33,9753%
- Education$2690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 585 | $510,970 |
| Gilead | 362 | $258,729 |
| EMD Serono, Inc. | 127 | $131,402 |
| Janssen Scientific Affairs, LLC | 54 | $42,466 |
| Merck | 84 | $33,486 |
| Janssen Products, LP | 29 | $22,646 |
| GSK | 3 | $4,847 |
| Theratechnologies Inc. | 10 | $2,475 |
| Johnson & Johnson(2 entities) | 33 | $905 |
| Pfizer | 25 | $515 |
| Cardinal Health 110 LLC | 1 | $400 |
| Novo Nordisk | 14 | $318 |
| Antares Pharma, Inc. | 12 | $248 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $241 |
| AbbVie(2 entities) | 10 | $217 |
| Lilly USA, LLC | 5 | $121 |
| Idorsia Pharmaceuticals US Inc | 5 | $93 |
| Amarin Pharma, Inc. | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| Hologic Sales And Service, LLC | 3 | $68 |
| Exact Sciences | 2 | $53 |
| Napo Pharmaceuticals Inc | 2 | $51 |
| Amgen(2 entities) | 2 | $41 |
| Endo Pharmaceuticals Inc. | 2 | $38 |
| Paratek Pharmaceuticals, Inc. | 2 | $37 |
| Eisai Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Clarus Therapeutics Inc. | 1 | $22 |
| Halozyme Inc | 1 | $21 |
| Dynavax Technologies Corporation | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,010,691 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 113 | $445,334 |
| DescovyEmtricitabine/Tenofov Alafenam | 191 | $431,496 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 103 | $430,639 |
| TivicayDolutegravir Sodium | 157 | $361,691 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 79 | $360,175 |
| JulucaDolutegravir/Rilpivirine | 87 | $342,229 |
| PrezcobixDarunavir/Cobicistat | 89 | $239,610 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 53 | $208,827 |
| DovatoDolutegravir Sodium/Lamivudine | 42 | $124,324 |
| IsentressRaltegravir Potassium | 45 | $90,577 |
| Isentress HdRaltegravir Potassium | 46 | $89,061 |
| OzempicSemaglutide | 37 | $67,030 |
| PifeltroDoravirine | 25 | $46,545 |
| JanuviaSitagliptin Phosphate | 53 | $40,574 |
| EliquisApixaban | 35 | $37,098 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy, Biktarvy, Genvoya, Tybost | $258,729 | $1,074,760360 claims |
| Viiv Healthcare CompanyTivicay, Juluca, Dovato | $510,970 | $828,244286 claims |
| Janssen Products, LPSymtuza | $22,646 | $360,17579 claims |
| MerckIsentress, Isentress Hd, Pifeltro, Januvia | $33,486 | $266,757169 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $905 | $264,811122 claims |
| Novo NordiskOzempic | $318 | $67,03037 claims |
| Janssen Scientific Affairs, LLCEdurant, Prezista | $42,466 | $54,74139 claims |
| PfizerEliquis | $515 | $37,09835 claims |
| AbbVieViberzi | $217 | $17,43311 claims |
| GSKBreo Ellipta | $4,847 | $6,19520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Seattle
- Scott RamseySeattle$230K
- Michael CairnsSeattle$144K
- Peiqing QianSeattle$117K
- Kevin ChungSeattle$35K
- David DaleSeattle$35K
- Catherine BenzigerSeattle$13K
- Christopher DoddSeattle$12K
- Dedra BuchwaldSeattle$11K
- Thao NguyenSeattle$10K
- James FloydSeattle$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.